How stressful life events are associated with depression: the mediating pathway of security in a clinical adolescent sample
White matter pathways mediating dorsolateral prefrontal TMS therapy for depression
Nature Neuroscience, Published online: 14 April 2026; doi:10.1038/s41593-026-02248-6
Seguin et al. show that the efficacy of transcranial magnetic stimulation for depression depends on how stimulation spreads through the brain’s wiring. Patients with shorter communication pathways between stimulated sites and mood-related regions had better clinical outcomes.
Evaluation of an Online ACT and Compassion-based Intervention for Disorders of Gut-Brain Interaction
Interventions: Behavioral: Acceptance and Commitment Therapy with explicit self-compassion training; Other: Education
Sponsors: Örebro University, Sweden; Sahlgrenska University Hospital; Göteborg University; Uppsala University
Not yet recruiting
Midwife-Led Digital Follow-Up After Cesarean Section
Interventions: Behavioral: Midwife-Led Digital Follow-Up Program
Sponsors: Inonu University; Kahramanmaras Sutcu Imam University
Not yet recruiting
Ganoderma Spores Modulate the Gut-Brain Axis
Interventions: Dietary Supplement: Sporoderm-removed Ganoderma lucidum spore powder (RGLS); Other: Placebo
Sponsors: Ling Zhiqiang
Not yet recruiting
Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder
Interventions: Drug: Dextromethorphan-Bupropion
Sponsors: Roger McIntyre; Axsome Therapeutics, Inc.
Recruiting
Co-Design of a Depression Self-Management Tool for Adolescent and Young Adult Cancer Survivors: Rapid Qualitative Analysis of Interview Feedback on a Prototype
STAT+: Access granted: CMS greenlights more than 150 participants for chronic care experiment
More than 150 companies and providers have been provisionally approved to participate in an experimental Medicare program meant to expand access to technology-supported chronic care. They include popular mental health apps, wearable device makers, a life sciences company tied to Google, and startups that help large health systems manage heart failure patients.
Announced late last year by the Center for Medicare and Medicaid Innovation, the ACCESS model will pay participants set rates to treat chronic conditions like diabetes, hypertension, high cholesterol, musculoskeletal pain, anxiety, and depression. The payments are tied to measurable health outcomes; the model is meant as an alternative to paying for individual technology services. The initial deadline to participate in the first ACCESS cohort was April 1, but CMMI Monday announced it will extend the deadline to allow more to join.
CMS officials say the large number of applications to participate in ACCESS exceeded their expectations and that the enthusiasm suggests modest payment rates and restrictions did not discourage digital health companies from applying. According to officials, most of the participants had not previously served Medicare patients.

